论文部分内容阅读
用于研究和临床试验的治疗活性化合物的特性是药物注册过程的一个重要方面。本文采用HPLC－MS法识别和阐明新的环氧酶／酯氧酶双重抑制剂tepoxalin（3－［5－（4-氯苯基）-1-（4-甲氧苯基）-3-吡唑基］N－羟基－N－甲基丙酰胺），以及合成大量药物时它的相关副产物和源于稳定性
The properties of therapeutically active compounds used in research and clinical trials are an important aspect of the drug registration process. In this paper, HPLC-MS was used to identify and elucidate the effects of a novel cyclooxygenase / esterase dual inhibitor, tepoxalin (3- [5- (4- chlorophenyl) -1- Oxazolyl] N-hydroxy-N-methylpropanamide), as well as its related by-products when synthesized in large quantities and from stability